Reach Us +44-1764910199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Toll-like Receptor: Breast Cancer Development and Immunotherapy

Breast cancer is well known leading causes of mortality in the females. Current studies have suggested that the imbalances in inflammatory and immune-associated proteins may also give rise to breast cancer and disease progression. Toll like receptors (TLRs) are essential components of innate immune system that protect the host against bacterial and viral infection. It not only express in innate immune cell, its expression also found in breast cancer cells. Activation of TLRs leads to the activation of inflammatory pathways. Recent reports provide such evidences, which suggest the important role of TLRs in breast cancer pathogenesis and recurrence. TLRs are not only involved in cancer development, but also involve in anticancer immunotherapy. There are some agonists and antagonist of TLRs, used in anticancer immunotherapy, is targeted in clinic successfully.



Emili Manna

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
Flyer image

Abstracted/Indexed in

  • Google Scholar
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs